KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Gross Margin (2017 - 2025)

Sarepta Therapeutics has reported Gross Margin over the past 9 years, most recently at 9.98% for Q4 2025.

  • For Q4 2025, Gross Margin fell 6992.0% year-over-year to 9.98%; the TTM value through Dec 2025 reached 61.81%, down 2142.0%, while the annual FY2025 figure was 61.81%, 2142.0% down from the prior year.
  • Gross Margin for Q4 2025 was 9.98% at Sarepta Therapeutics, down from 62.25% in the prior quarter.
  • Over five years, Gross Margin peaked at 96.04% in Q4 2022 and troughed at 77.6% in Q3 2022.
  • A 5-year average of 50.72% and a median of 82.89% in 2021 define the central range for Gross Margin.
  • Biggest five-year swings in Gross Margin: crashed -16523bps in 2022 and later soared 16563bps in 2023.
  • Year by year, Gross Margin stood at 84.24% in 2021, then grew by 14bps to 96.04% in 2022, then decreased by 0bps to 95.9% in 2023, then decreased by -17bps to 79.91% in 2024, then crashed by -88bps to 9.98% in 2025.
  • Business Quant data shows Gross Margin for SRPT at 9.98% in Q4 2025, 62.25% in Q3 2025, and 75.04% in Q2 2025.